Earnings ·
Bristol-Myers Squibb reported second quarter 2026 total revenues of $13.0 billion, a 6% increase from the prior year…
BMYMPBristol Myers Squibb Co
Bristol-Myers Squibb reported second quarter 2026 total revenues of $13.0 billion, a 6% increase from the prior year period. GAAP earnings per share were $1.62, while non-GAAP EPS reached $2.04. The company raised its full-year 2026 revenue guidance to approximately $49.0–$50.0 billion and increased its non-GAAP EPS outlook to $6.75–$7.00. Growth Portfolio revenues rose 15% to $7.6 billion, driven by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, and Opdualag. The company also announced FDA acceptance of supplemental applications for Reblozyl in myelofibrosis and mezigdomide in multiple myeloma, alongside strategic AI partnerships with NVIDIA and Anthropic. Bristol-Myers Squibb is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines.